(Reuters) – Novavax Inc said on Tuesday its updated protein-based COVID-19 vaccine generated neutralizing antibody responses to the “Eris” subvariant in preclinical studies.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Shilpi Majumdar)
(Reuters) – Novavax Inc said on Tuesday its updated protein-based COVID-19 vaccine generated neutralizing antibody responses to the “Eris” subvariant in preclinical studies.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Shilpi Majumdar)
